In an effort to make the AUC usable, meaningful, and as up-to-date as possible, the writing group was asked to develop AUC specifically for coronary revascularization in ACS including STEMI to coincide with the recently published focused update of the STEMI guidelines (5). A new separate AUC document specific to SIHD is under preparation and will be forthcoming. The goal of the writing group was to develop clinical indications (scenarios) that reflect typical situations encountered in everyday practice, which are then classified by a separate rating panel using methodology previously described in detail (12) ( Figure 1 ). In addition, step-by-step flow charts are provided to help use the criteria.
METHODS

Indication Development
A multidisciplinary writing group consisting of cardiovascular health outcomes researchers, interventional cardiologists, cardiothoracic surgeons, and general cardiologists was convened to review and revise the coronary revascularization AUC.
The revascularization AUC are on the basis of our current understanding of procedure outcomes plus the potential patient benefits and risks of the revascularization ongoing review of one's practice using these criteria will help guide more effective, efficient, and equitable allocation of healthcare resources, and ultimately lead to better patient outcomes. Under no circumstances should the AUC be used as the sole means to adjudicate or determine payment for individual patients-rather, the intent of the AUC is to provide a framework to evaluate overall clinical practice and to improve the quality of care.
In developing these AUC for coronary revascularization, the rating panel was asked to rate each indication using the following definition of appropriate use: 
Appropriate Use Definition and Ratings
In rating these criteria, the rating panel was asked to assess whether the use of revascularization for each indication is "appropriate care," "may be appropriate care," or "rarely appropriate care" using the following definitions and their associated numeric ranges.
Median Score 7 to 9: Appropriate Care
An appropriate option for management of patients in this population due to benefits generally outweighing risks;
an effective option for individual care plans, although not always necessary depending on physician judgment and patient-specific preferences (i.e., procedure is generally acceptable and is generally reasonable for the indication).
Median Score 4 to 6: May Be Appropriate Care
At times, an appropriate option for management of patients in this population due to variable evidence or agreement regarding the risk-benefit ratio, potential
Patel et al. 
Scope of Indications
The indications for coronary revascularization in ACS were developed considering the following common variables: . 
DEFINITIONS
Definitions of terms used throughout the indication set are listed here. These definitions were provided to and discussed with the rating panel before the rating of indications. The writing group assumed that noninvasive assessments of coronary anatomy (i.e., cardiac computed tomography, cardiac magnetic resonance angiography)
provide anatomic information that is potentially similar to X-ray angiography. However, these modalities do not currently provide information on ischemic burden and are not assumed to be present in the clinical scenarios.
Indication
A set of patient-specific conditions defines an "indica- 
Culprit Stenosis
The phrase "culprit stenosis" is often used interchangeably with "infarct-related artery" to identify the coronary artery stenosis and/or artery responsible for the ACS. In this document, the phrase "culprit stenosis or culprit artery" is preferred, because in the setting of unstable angina there may be a culprit stenosis or culprit artery, but by definition, there is no evidence of a myocardial infarction. (Tables A and B) .
Symptoms of Myocardial Ischemia
Stress Testing and Risk of Findings on Noninvasive Testing
Stress testing and coronary CTA are commonly used for both diagnosis and risk stratification of patients with coronary artery disease or those with suspected ACS.
Patel et al. Low-risk stress test findings: associated with a <1%
per year cardiac mortality rate.
Intermediate-risk stress test findings: associated with a 1% to 3% per year cardiac mortality rate.
High-risk stress test findings: associated with a >3%
per year cardiac mortality rate. However, the timing of treatment and criteria for nonculprit stenosis treatment varied among these 3 studies as shown in Patel et al. Revascularization of the Presumed Culprit Artery by PCI (Primary PCI)
The Role of Patient Preference in the AUC
J A C C V O L . -, NO. -,
1.
n Less than or equal to 12 hours from onset of symptoms A (9) 2. n Onset of symptoms within the prior 12-24 hours AND n Severe HF, persistent ischemic symptoms, or hemodynamic or electrical instability present
3.
n Onset of symptoms within the prior 12-24 hours AND n Stable without severe HF, persistent ischemic symptoms, or hemodynamic or electrical instability
M (6)
Successful Treatment of the Culprit Artery by Primary PCI Followed by Immediate Revascularization of 1 or More Nonculprit Arteries During the Same Procedure
4.
n Cardiogenic shock persisting after PCI of the presumed culprit artery n PCI or CABG of 1 or more additional vessels A (8)
5.
n Stable patient immediately following PCI of the presumed culprit artery n One or more additional severe stenoses M (6)
6.
n Stable patient immediately following PCI of the presumed culprit artery n One or more additional intermediate (50%-70%) stenoses
M (4)
The number in parenthesis next to the rating reflects the median score for that indication.
A ¼ appropriate; CABG ¼ coronary artery bypass graft; HF ¼ heart failure; M ¼ may be appropriate; PCI ¼ percutaneous coronary intervention; R ¼ rarely appropriate; STEMI ¼ ST-segment elevation myocardial infarction.
presence or absence of symptoms as noted. Scenarios 4 to 6 in Table 1 .1 specifically address treatment of 1 or more nonculprit stenoses during the same procedure as treatment of the culprit stenosis. Because these scenarios are specific for nonculprit treatment immediately following primary PCI, the criteria for treatment used in DANAMI3-PRIMULTI cannot be applied in this table.
As noted in PCI of the Presumed Culprit Artery After Fibrinolysis
7.
n Evidence of failed reperfusion after fibrinolysis (e.g., failure of ST-segment resolution, presence of acute severe HF, ongoing myocardial ischemia, or unstable ventricular arrhythmias)
A (9) 8. n Stable after fibrinolysis AND n Asymptomatic (no HF, myocardial ischemia, or unstable ventricular arrhythmias) AND n PCI performed 3-24 hours after fibrinolytic therapy A (7) 9. n Stable after fibrinolysis AND n Asymptomatic (no HF, myocardial ischemia, or unstable ventricular arrhythmias) AND n PCI >24 hours after onset of STEMI
M (5)
The number in parenthesis next to the rating reflects the median score for that indication. 
A (7)
A ¼ appropriate; CABG ¼ coronary artery bypass graft; FFR ¼ fractional flow reserve; M ¼ may be appropriate; PCI ¼ percutaneous coronary intervention; R ¼ rarely appropriate; STEMI ¼ ST-segment elevation myocardial infarction. 17. n Patient stabilized after presentation n Low-risk features for clinical events (e.g., TIMI score #2) n Revascularization of 1 or more coronary arteries
M (5)
The number in parenthesis next to the rating reflects the median score for that indication. For STEMI patients presenting more than 12 and up to 24
hours from symptom onset but with no signs of clinical instability, revascularization was rated as "may be appropriate," indicating that many on the technical panel consider it reasonable to revascularize such patients.
Furthermore, nonculprit artery revascularization at the time of primary PCI was rated as "may be appropriate," but because this is an emerging concept on the basis of relatively small studies, clinical judgment by the operator is encouraged.
For STEMI patients initially treated with fibrinolysis, revascularization was rated as "appropriate therapy" in the setting of suspected failed fibrinolytic therapy or in stable and asymptomatic patients from 3 to 24 hours after fibrinolysis. In the setting of suspected failed fibrinolysis, the need for revascularization is usually immediate, whereas in stable patients with apparent successful fibrinolysis, revascularization can be delayed for up to 24
hours. For stable patients >24 hours after fibrinolysis, revascularization was rated as "may be appropriate."
Revascularization soon after apparent successful fibrinolysis is supported by data and guideline recommendations about the management of patients transferred from centers where PCI is not available.
Nonculprit artery revascularization during the index hospitalization after primary PCI or fibrinolysis was also Specifically, all panelists are asked to provide disclosure statements of all relationships that might be perceived as real or potential conflicts of interest. These statements were reviewed by the Appropriate Use Criteria Task Force, discussed with all members of the rating panel at the faceto-face meeting, and updated and reviewed as necessary.
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